Skip to main content

Delgado Gil, Raquel

Institutions of which they are part

Predoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Delgado Gil, Raquel

Institutions of which they are part

Predoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Precision Endometriosis Research: Integrating Molecular Classification, In Vitro Modeling, and Personalized Therapeutic Strategies

IP: Eva Colas Ortega
Collaborators: Elena Suarez Salvador, Francesc Xavier Serra Marin, Carina Masferrer Ferragutcasas, Anna Ruano Lopez, Josep Castellví Vives, Sonia Monreal Clua, Diana Alejandra Guerrero Lojano, Raquel Delgado Gil
Funding agency: Fundació La Marató de TV3
Funding: 200000
Reference: 202407-10
Duration: 20/02/2025 - 19/02/2028

Precision Endometriosis Research: Integrating Molecular Classification, In Vitro Modeling, and Personalized Therapeutic Strategies

IP: Eva Colas Ortega
Collaborators: Elena Suarez Salvador, Francesc Xavier Serra Marin, Carina Masferrer Ferragutcasas, Anna Ruano Lopez, Josep Castellví Vives, Sonia Monreal Clua, Diana Alejandra Guerrero Lojano, Raquel Delgado Gil
Funding agency: Fundació La Marató de TV3
Funding: 200000
Reference: 202407-10
Duration: 20/02/2025 - 19/02/2028

Development of non-invasive molecular diagnosis of endometriosis

IP: Eva Colas Ortega
Collaborators: Raquel Delgado Gil, Miriam Izquierdo Sans
Funding agency: Fundació Institut de Recerca HUVH
Funding: 102820.06
Reference: VHIR-PHD-2023-005
Duration: 01/12/2023 - 30/11/2027

Cytomark - Desarrollo de un test diagnóstico personalizado y no invasivo de cáncer de endometrio en el fluido cervical

IP: Eva Colas Ortega
Collaborators: Vicente Bebia Conesa, Angel García Jiménez, Carina Masferrer Ferragutcasas, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Raquel Delgado Gil, Beatriz Villafranca Magdalena, Melek Denizli , Valeria Tubita
Funding agency: Asociación Española Contra el Cáncer
Funding: 188000
Reference: PERME212443COLA
Duration: 01/01/2022 - 31/01/2026

Related news

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The study evaluated the results of combining SYD985, a HER2 antibody conjugated to a potent cytotoxic drug, and niraparib, an inhibitor of DNA damage repair.

Researchers from the centre took part in international debates on AI in healthcare, spin-offs emerging from research were presented, and several initiatives linked to VHIR received recognition in the field of entrepreneurship.

Related professionals

Iñaki Mimendia  Sancho

Iñaki Mimendia Sancho

Senior researcher
Reconstructive Surgery of the Locomotor System
Read more
Gemma  Duarri Llado

Gemma Duarri Llado

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Carmen Sanchez Suarez

Carmen Sanchez Suarez

Research assistant
Molecular Imaging and Therapy
Read more
Ana Moreno Fernández

Ana Moreno Fernández

Cap d'Unitat
Financial Control Unit
Finance Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.